Kamada Pharmaceuticals signed a new marketing agreement in Israel for 6 new products

Kamada Pharmaceuticals today announced the signing of a new marketing agreement in Israel for 6 new products, imitations of biological drugs (biosimilers), including osteoporosis drug (bone depletion), already approved for marketing in the US and five other products awaiting approval. By 2025, the company's revenues in the peak years will reach about $ 20-30 million a year, with the company's share today dropping by about 1%, and its value stands at slightly more than NIS 1 billion.
About a week and a half ago, the Private Equity Fund became the largest shareholder in Qamhada, having acquired 12% of the company's shares from long-time shareholders for $ 30 million. Phimi bought the shares at the market price at the time of purchase ($ 6 per share) and since then the stock has added about 25%.
In the early 2000s, it underwent a successful strategic change process, beginning to produce value-added products, bringing two new products of this kind: a hereditary lung disease treatment product and a rabies treatment product. These products are, in fact, responsible for most of the company's revenue today, about 75% of the company's revenues in the first 9 months of 2019 ($ 72 million $ 95 million). On the basis of the two value-added products, Kamada has grown significantly and consistently in recent years.
Next year production rights for the company's main product, Galicia for the treatment of emphysema, should pass to its distributor, Takeda. The next value-added product the company plans to bring to the market, a remedy for inherited emphysema, will not become commercial until 2024 at the earliest. So Kamada was now free to strengthen the smaller legs in her business.